邮件订阅
RSS
Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China
-
摘要: 核医学诊疗一体化是将放射性核素显像与内放射治疗相结合，从而实现疾病的可视化诊断和精准治疗。目前，核医学诊疗一体化已在分化型甲状腺癌、嗜铬细胞瘤、恶性肿瘤骨转移、神经内分泌肿瘤、前列腺癌中发挥重要作用。我国医用放射性核素及放射性药物短缺，严重依赖进口，存在“卡脖子”问题，应加强诊疗一体化医用放射性核素及放射性药物的自主生产与创新研发力度，以促进核医学诊疗一体化更好地服务我国临床实践。Abstract: Theranostics in nuclear medicine is the combination of radionuclide imaging and internal radiotherapy, so as to realize the visualized diagnosis and precise treatment of diseases. At present, theranostics of nuclear medicine has played an important role in differentiated thyroid carcinoma, pheochromocytoma, bone metastases, neuroendocrine tumors and prostate cancer. China's medical radionuclides and radionuclide medicines are in short supply and heavily dependent on imports, so there is a "bottleneck" problem. It is necessary to strengthen the independent production, innovation and research of medical radionuclides and radiopharmaceutics of theranostics, so as to promote theranostics of nuclear medicine to better serve China's clinical practice.
-
Keywords:
- theranostics /
- nuclear medicine /
- radionuclide /
- thyroid carcinoma /
- neuroendocrine neoplasms
-
诊断性放射性药物 治疗性放射性药物 临床诊断与治疗病种 Na123I、Na124I Na131I 分化型甲状腺癌 123I-MIBG、124I-MIBG 131I-MIBG 嗜铬细胞瘤 99mTc-MDP、18F-NaF 89SrCl2、223RaCl2 恶性肿瘤骨转移 68Ga-DOTATATE 177Lu-DOTATATE 神经内分泌肿瘤 68Ga-PSMA 177Lu-PSMA 前列腺癌 
下载: 导出CSV
表 2 具有应用前景的诊疗一体化核素
诊断性放射性核素 配对的治疗性放射性核素 123I/124I 131I 68Ga 177Lu 68Ga 225Ac 64Gu 67Gu 44Sc 47Sc 152Tb 161Tb 86Y 90Y 99mTc 188Re
下载: 导出CSV
-
[1] Filippi L, Chiaravalloti A, Schillaci O, et al. Theranostic approaches in nuclear medicine: current status and future prospects[J]. Expert Rev Med Devices, 2020, 17: 331-343. DOI: 10.1080/17434440.2020.1741348
[2] Jokar N, Assadi M, Yordanova A, et al. Bench-to-Bedside Theranostics in Nuclear Medicine[J]. Curr Pharm Des, 2020, 26: 3804-3811. DOI: 10.2174/1381612826666200218104313
[3] Solnes LB, Shokeen M, Pandit-Taskar N. Novel Agents and Future Perspectives on Theranostics[J]. Semin Radiat Oncol, 2021, 31: 83-92. DOI: 10.1016/j.semradonc.2020.07.010
[4] O'Dwyer E, Bodei L, Morris MJ. The Role of Theranostics in Prostate Cancer[J]. Semin Radiat Oncol, 2021, 31: 71-82. DOI: 10.1016/j.semradonc.2020.07.004
[5] 张锦明, 杜进. 中国放射性药物制备的现状及展望[J]. 同位素, 2019, 32: 178-185. DOI: 10.7538/tws.2019.32.03.0178 Zhang JM, Du J. Preparation of Radiopharmaceuticals in China: Current Status and Prospects[J]. Tongweisu, 2019, 32: 178-185. DOI: 10.7538/tws.2019.32.03.0178
[6] Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1588-1601. DOI: 10.1007/s00259-017-3728-y
[7] Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. DOI: 10.1056/NEJMoa1607427
[8] Ali N, Sebastian C, Foley RR, et al. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy[J]. Nucl Med Commun, 2006, 27: 165-169. DOI: 10.1097/01.mnm.0000194397.20067.b6
[9] Nagarajah J, Janssen M, Hetkamp P, et al. Iodine Symporter Targeting with 124I/131I Theranostics[J]. J Nucl Med, 2017, 58: 34S-38S. DOI: 10.2967/jnumed.116.186866
[10] Gulec SA, Kuker RA, Goryawala M, et al. 124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis[J]. Thyroid, 2016, 26: 441-448. DOI: 10.1089/thy.2015.0482
[11] Furuta N, Kiyota H, Yoshigoe F, et al. Diagnosis of pheochromocytoma using[123I]-compared with[131I]-metaiodobenzylguanidine scintigraphy[J]. Int J Urol, 1999, 6: 119-124. DOI: 10.1046/j.1442-2042.1999.06310.x
[12] Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma[J]. J Nucl Med, 2019, 60: 623-630. DOI: 10.2967/jnumed.118.217463
[13] Willegaignon J, Crema KP, Oliveira NC, et al. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures[J]. Clin Nucl Med, 2018, 43: 572-578. DOI: 10.1097/RLU.0000000000002158
[14] Weber M, Schmitz J, Maric I, et al. Diagnostic performance of 124I-m-iodobenzylguanidine PET/CT in patients with pheochromocytoma[J]. J Nucl Med, 2021. doi: 10.2967/jnumed.121.262797.
[15] 支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志, 2015, 37: 67-78. DOI: 10.3760/cma.j.issn.0253-3766.2015.01.014 Zhi XY, Shi YK, Yu JM. Standards for the diagnosis and treatment of primary lung cancer(2015 version) in China[J]. Zhonghua Zhongliu Zazhi, 2015, 37: 67-78. DOI: 10.3760/cma.j.issn.0253-3766.2015.01.014
[16] 陈跃, 赵军, 吴湖炳, 等. 18F-NaF PET/CT骨显像操作指南[J]. 中华核医学与分子影像杂志, 2016, 36: 76-78. DOI: 10.3760/cma.j.issn.2095-2848.2016.01.018 Chen Y, Zhao J, Wu HB, et al. Operation guide of 18F-NaF PET/CT bone imaging[J]. Zhonghua Heyixue Yu Fenzi Yingxiang Zazhi, 2016, 36: 76-78. DOI: 10.3760/cma.j.issn.2095-2848.2016.01.018
[17] Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 846-859. DOI: 10.1007/s00259-018-3947-x
[18] Manafi-Farid R, Masoumi F, Divband G, et al. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain[J]. J Clin Med, 2020, 9: 2622. DOI: 10.3390/jcm9082622
[19] Sadremomtaz A, Masoumi M. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides[J]. J Med Imaging Radiat Sci, 2019, 50: 272-279. DOI: 10.1016/j.jmir.2018.12.005
[20] Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT[J]. AJR Am J Roentgenol, 2018, 211: 267-277. DOI: 10.2214/AJR.18.19881
[21] 陈跃, 霍力, 兰晓莉, 等. 68Ga-DOTA-生长抑素受体PET/CT神经内分泌肿瘤显像操作指南[J]. 中国医学影像技术, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-DOTA-conjugated somatostatin receptor PET/CT imaging in neuroendocrine neoplasms[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm
[22] Zhang J, Song Q, Cai L, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2020, 146: 1533-1543. DOI: 10.1007/s00432-020-03181-2
[23] Farolfi A, Lima GM, Oyen W, et al. Molecular Imaging and Theranostics-A Multidisciplinary Approach[J]. Semin Nucl Med, 2019, 49: 247-254. DOI: 10.1053/j.semnuclmed.2019.02.002
[24] Hamed M, Basha M, Ahmed H, et al. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy[J]. Acad Radiol, 2019, 26: 450-460. DOI: 10.1016/j.acra.2018.05.020
[25] 陈跃, 霍力, 兰晓莉, 等. 68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南[J]. 中国医学影像技术, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-PSMA PET/CT imaging in prostatic cancer[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm
[26] Yadav MP, Ballal S, Sahoo RK, et al. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis[J]. AJR Am J Roentgenol, 2019, 213: 275-285. DOI: 10.2214/AJR.18.20845
[27] Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 2536-2544. DOI: 10.1007/s00259-019-04485-3
[28] Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients[J]. Theranostics, 2020, 10: 9364-9377. DOI: 10.7150/thno.48107
[29] Goldsmith SJ. Targeted Radionuclide Therapy: A Historical and Personal Review[J]. Semin Nucl Med, 2020, 50: 87-97. DOI: 10.1053/j.semnuclmed.2019.07.006
[30] Jokar N, Velikyan I, Ahmadzadehfar H, et al. Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology[J]. Clin Nucl Med, 2021, 46: e410-e420. DOI: 10.1097/RLU.0000000000003678
[31] Jadvar H. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies[J]. Cancer Biother Radiopharm, 2020, 35: 475-484. DOI: 10.1089/cbr.2019.3340
[32] Brito AE, Etchebehere E. Radium-223 as an Approved Modality for Treatment of Bone Metastases[J]. Semin Nucl Med, 2020, 50: 177-192. DOI: 10.1053/j.semnuclmed.2019.11.005
[33] Frantellizzi V, Cosma L, Brunotti G, et al. Targeted Alpha Therapy with Thorium-227[J]. Cancer Biother Radiopharm, 2020, 35: 437-445. DOI: 10.1089/cbr.2019.3105
[34] Anand A, Trägårdh E, Edenbrandt L, et al. Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients[J]. J Nucl Med, 2020, 61: 671-675. DOI: 10.2967/jnumed.119.231100
计量
- 文章访问数:
- HTML全文浏览量:
- PDF下载量:
